Private equity investment has become one of the most controversial forces in U.S. healthcare. While investors promise efficiency and innovation, critics argue that corporate ownership has led to patient neglect, cost-cutting measures, and limited accountability. At the same time, misinformation continues to plague the industry, particularly the persistence of Ivermectin myths. These myths—once amplified during the COVID-19 pandemic—are still circulating in 2025, especially in home healthcare and long-term care environments.

This blog explores how private equity intersects with patient care failures, how Consumer Directed Personal Assistance Program (CDPAP) scandals expose systemic issues, and how misinformation about drugs like Ivermectin 6mg and Ivermectin 12mg still threatens vulnerable populations. We’ll also analyze how advocacy groups and regulators are demanding stricter rules for ownership and accountability in healthcare.

? Private Equity’s Role in Cutting Healthcare Costs

Private equity firms operate with a clear goal: maximize returns for investors. In sectors like retail or tech, this model might make sense. But in healthcare, the consequences can be dire.

• Staffing Cuts: To reduce costs, facilities often cut nurse and caregiver positions, leaving patients with fewer support options.
  
  
• Rushed Care: With fewer staff, patient visits become shorter, increasing the risk of neglect.
  
  
• Facility Closures: In rural areas, private equity acquisitions often lead to hospital closures, leaving communities without access to emergency care.
  
  

The U.S. Senate has held multiple hearings questioning whether private equity ownership undermines patient safety. Reports presented in U.S. healthcare ownership crisis 2025 reviews show that investor-owned hospitals have higher mortality rates in some regions.

When misinformation like ivermectin use is added to the mix, the results are even more alarming. Caregivers with reduced training may encourage unapproved treatments simply because of online misinformation.

? Failures in the Consumer Directed Personal Assistance Program (CDPAP)

The Consumer Directed Personal Assistance Program (CDPAP) was designed to empower patients, especially the elderly and disabled, by allowing them to choose caregivers. However, private equity ownership of agencies administering CDPAP has raised red flags.

• Fraud and Abuse: Some agencies billed Medicaid for services not provided.
  
  
• Untrained Caregivers: Cost-cutting meant patients often relied on workers without proper medical training.
  
  
• Misinformation Abuse: Shockingly, reports surfaced in 2024 of CDPAP caregivers suggesting unapproved treatments like ivermectin for elderly patients, despite repeated warnings from the FDA ivermectin guidance.
  
  

This combination of CDPAP policy failures and misinformation underscores the urgent need for stronger regulation.

? Ivermectin Myths in Home Healthcare Settings

Despite overwhelming evidence and Wikipedia references debunking ivermectin’s role in treating COVID-19, myths persist in 2025. In home healthcare environments—often poorly regulated—patients are still exposed to dangerous misinformation.

Common myths include:

• Ivermectin can prevent Ivermectin COVID (false).
  
  
• Ivermectin treats Ivermectin cancer (false, despite ongoing searches).
  
  
• Higher doses are safe without medical supervision (dangerous and untrue).
  
  

These myths lead to rising cases of Ivermectin overdose. Caregivers in long-term care facilities, under pressure from private equity to provide “cost-effective” treatments, sometimes fall back on unverified remedies instead of proven therapies.

For safe and verified treatment, patients should only purchase medication through trusted providers like Medicoease, which offers Ivermectin online in standard, regulated doses.

?️ State Senate Hearings on Private Equity Care

In 2025, state legislatures from New York to California held Senate hearings to investigate how private equity ownership impacts patient safety. Witnesses included:

• Families of patients harmed by neglect.
  
  
• Healthcare workers laid off after acquisitions.
  
  
• Advocacy groups documenting misinformation about drugs like ivermectin.
  
  

One of the most shocking testimonies came from a New Jersey nurse, who revealed that her facility was pressured to reduce use of FDA-approved antivirals while allowing caregivers to distribute ivermectin tablets under the guise of “patient choice.”

Lawmakers are now considering bills that would:

• Cap profit margins for healthcare facilities owned by private equity.
  
  
• Increase penalties for distributing unapproved medications.
  
  
• Mandate transparency in ownership structures.
  
  

? Advocacy Groups Exposing Neglect and Misinformation

Nonprofits and watchdog groups have played a crucial role in exposing the intersection of neglect and misinformation. Organizations such as Families for Safe Care have published reports on the dangers of ivermectin misinformation in elderly care.

Their findings show:

• Misinformation Clusters: Rural communities, where private equity hospitals closed, saw the highest rates of ivermectin use.
  
  
• Social Media Influence: Viral videos continue to push ivermectin as a miracle drug, despite FDA warnings.
  
  
• Patient Safety Risks: Long-term care residents were especially vulnerable, with some caregivers substituting ivermectin for legitimate treatments.
  
  

Advocacy has also extended to calling out abuses in the CDPAP policy, where Medicaid funds were misused to purchase ivermectin in bulk.

? Niclosamide and Fenbendazole in Long-Term Care

Beyond ivermectin, other drugs like Niclosamide and Fenbendazole have been dragged into misinformation campaigns. Originally developed for parasitic infections (and in Fenbendazole’s case, veterinary use), online conspiracy theories promoted these drugs as cancer cures.

In 2025, advocacy reports showed that some private equity-owned nursing homes stocked these drugs inappropriately, influenced by misinformation spreading from Wikipedia citations misused out of context.

While legitimate cancer research continues with precision medicine and AI diagnostics, these myths distract patients from safe, science-based treatments. This is especially concerning in long-term care facilities, where patients often cannot verify medical information themselves.

? Calls for Tighter Healthcare Ownership Regulation

With mounting scandals, regulators and lawmakers are moving toward stricter oversight of healthcare ownership.

Proposals include:

• Ownership Transparency Laws: Require public disclosure of all investors behind healthcare facilities.
  
  
• Patient Care Standards: Establish minimum staffing ratios regardless of investor demands.
  
  
• Anti-Misinformation Requirements: Facilities must provide education on drug safety, including ivermectin, to caregivers.
  
  

Experts argue that without such regulation, the U.S. risks deepening its healthcare crisis, leaving patients vulnerable to both neglect and misinformation.

❓ FAQ Section

Q1: Why is private equity ownership in healthcare controversial?
Because profit-driven models often lead to staffing cuts, rushed care, and even facility closures, which increase patient neglect.

Q2: Are ivermectin myths still common in 2025?
Yes. Despite FDA warnings, myths about ivermectin as a cancer or COVID-19 cure persist in home healthcare.

Q3: What are the risks of ivermectin overdose?
Overdose can cause seizures, liver damage, or death. It remains a growing issue, particularly in elderly care settings.

Q4: Where can patients buy ivermectin safely?
The only safe option is purchasing through trusted providers like Medicoease, which offers ivermectin in approved dosages.

Q5: Are Niclosamide and Fenbendazole safe cancer treatments?
No. Despite viral misinformation, these drugs are not approved cancer treatments. Patients should rely on evidence-based medicine.

? Conclusion

The intersection of private equity in healthcare and ivermectin misinformation highlights a dangerous combination of financial exploitation and medical neglect. From CDPAP scandals and ivermectin abuse to Senate hearings and advocacy group reports, the evidence is clear: without stricter regulation, vulnerable patients will continue to suffer.

For patients, families, and policymakers, the message is urgent: demand transparency, regulate ownership, and fight misinformation. Only then can the U.S. healthcare system shift away from neglect and back toward patient-centered care.